Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$107.20
Price+0.19%
$0.20
1Y
Price
Market Cap
$12.715b
Large
Price/Earnings 3y Avg5y Avg
20x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+66.5%
EBITDA Margin+47.8%
Net Profit Margin+49.2%
Free Cash Flow Margin+66.5%
EBITDA Margin+47.8%
Net Profit Margin+49.2%
Free Cash Flow MarginRevenue
$1.664b
+19.1%
1y CAGR+26.4%
3y CAGR+26.2%
5y CAGREarnings
$413.596m
+30.5%
1y CAGR+19.9%
3y CAGR+24.7%
5y CAGREPS
$3.35
+30.9%
1y CAGR+22.9%
3y CAGR+28.7%
5y CAGRBook Value
$143.543m
$2.577b
Assets$2.434b
Liabilities$2.147b
DebtDebt to Assets
83.3%
3x
Debt to EBITDAFree Cash Flow
$806.224m
+25.1%
1y CAGR+29.4%
3y CAGR+36.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company